Video
GU toxicity determined by germline variants in retrospective prostate cancer study
Author(s):
“What we found was a signature that you can apply to patients to find out whether they're at high risk of these moderate or greater urinary side effects in the long term, and it did appear to depend on the type of radiation they were receiving,” says Amar U. Kishan, MD.
Video Player is loading.
In this video, Amar U. Kishan, MD, discusses the results of the study, “Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.” Kishan is an associate professor in the department of radiation oncology, chief of genitourinary oncology service, and vice chair of clinical and translational research at the University of California, Los Angeles.
Related Videos
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Alternative treatments and patient communication for genitourinary syndrome of menopause
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Study results affirm effectiveness of evolving prostate cancer therapies
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Related Content
